MedTrace Logo

Tocilizumab in Corticosteroid-Resistant Graves' Orbitopathy (Thyroid Eye Disease)

NCT06367517 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 30

Last updated 2024-04-16

No results posted yet for this study

Summary

The aim of this study is to evaluate the efficacy and safety of Tocilizumab as second/third line treatment in patients with Active Moderate-to-Severe Corticosteroid-Resistant Thyroid Eye Disease.

Conditions

  • Orbitopathy, Graves
  • Thyroid Eye Disease
  • Ophthalmopathy

Interventions

DRUG

Tocilizumab

Tocilizumab administrated at a dose of 8 mg/kg, given once every four weeks

Sponsors & Collaborators

  • Medical University of Warsaw

    lead OTHER

Principal Investigators

  • Tomasz Bednarczuk, MD, PHD · Medical University of Warsaw

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-05-20
Primary Completion
2025-05-20
Completion
2026-05-20

Countries

  • Poland

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06367517 on ClinicalTrials.gov